Popular Trials
Monoclonal Antibodies
Chemotherapy + Monoclonal Antibody Therapy for Non-Hodgkin's Lymphoma
Recruiting4 awardsPhase 3
Palm Springs, California
This trial is comparing two different ways of treating non-Hodgkin's lymphoma with chemotherapy, using either one monoclonal antibody or two monoclonal antibodies.
Corticosteroid
Combination Therapy for Acute Lymphoblastic Leukemia
Recruiting3 awardsPhase 2
Salt Lake City, Utah
This trial will study a new multi-drug chemotherapy regimen for treating Acute Lymphoblastic Leukemia in adults. The regimen includes drugs that have been used to treat pediatric patients in the past, as well as new drugs PEG-asparaginase and E. coli asparaginase. Researchers hope to learn more about the disease and how it responds to standard chemotherapy drugs.
Alkylating agents
Chemotherapy +/− Bevacizumab for Breast Cancer
Recruiting1 awardPhase 3
Scottsdale, Arizona
This trial is testing doxorubicin hydrochloride, cyclophosphamide, and paclitaxel with or without bevacizumab to see how well they work in treating patients with lymph node-positive or high-risk, lymph node-negative breast cancer.
Popular Filters
Phase 3 Trials
Radiation
Radiation + Chemotherapy for Medulloblastoma
Recruiting2 awardsPhase 3
Las Vegas, Nevada
This trial is looking at whether standard-dose radiation therapy, versus reduced-dose, is more effective in children 3-7 years of age who have had surgery for newly diagnosed standard-risk medulloblastoma.
Trials With No Placebo
Alkylating agents
Surgery, Radiation & Chemotherapy for Early-Stage Hodgkin's Lymphoma
Recruiting2 awardsPhase 2
Salt Lake City, Utah
This trial is studying how well surgery, radiation therapy, and/or combination chemotherapy work in treating young patients with newly diagnosed stage I or stage II lymphocyte predominant Hodgkin disease.
Radiation
Radiation + Chemotherapy for Medulloblastoma
Recruiting2 awardsPhase 3
Las Vegas, Nevada
This trial is looking at whether standard-dose radiation therapy, versus reduced-dose, is more effective in children 3-7 years of age who have had surgery for newly diagnosed standard-risk medulloblastoma.
Tyrosine Kinase Inhibitor
Imatinib or Dasatinib for Chronic Myeloid Leukemia
Recruiting1 awardPhase 2
Montrose, Colorado
This trial looks at two different doses of imatinib mesylate and dasatinib to see how well they work in treating patients with previously untreated chronic phase chronic myelogenous leukemia.
View More Related Trials
Frequently Asked Questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.